68Ga-Trivehexin PET/CT在乳腺癌淋巴结评估中优于18F-FDG PET/CT
一例左上象限乳腺癌患者先后接受18F-FDG PET/CT与68Ga-Trivehexin PET/CT,后者在原发肿瘤、左内乳淋巴结及腋窝淋巴结的放射性示踪剂摄取高于前者,但纵隔及左肺门FDG阳性淋巴结未见Trivehexin摄取,隆突下淋巴结活检为良性细胞学。该病例表明,对乳腺癌可疑但难以活检区域的淋巴结使用68Ga-Trivehexin PET/CT有助于准确分期。
要点
- 68Ga-Trivehexin PET/CT在原发肿瘤、左内乳淋巴结及腋窝淋巴结的摄取高于18F-FDG PET/CT。
- 纵隔及左肺门FDG阳性淋巴结未见Trivehexin摄取,隆突下淋巴结活检为良性细胞学。
- 对难以活检区域的可疑淋巴结,68Ga-Trivehexin PET/CT可能有助于乳腺癌准确分期。
核心结论
- 对乳腺癌可疑但难以活检区域的淋巴结使用68Ga-Trivehexin PET/CT可能有助于准确分期。
研究设计与样本
- 一例左上象限乳腺癌患者的病例报告,患者曾接受18F-FDG PET/CT检查并随后接受68Ga-Trivehexin PET/CT检查。
主要发现
- 68Ga-Trivehexin PET/CT在原发肿瘤、左内乳淋巴结及腋窝淋巴结的放射性示踪剂摄取高于18F-FDG PET/CT。
- 纵隔及左肺门FDG阳性淋巴结中未观察到Trivehexin摄取。
- 隆突下淋巴结活检显示良性细胞学结果。
临床怎么用
- 作者认为,对乳腺癌可疑但难以活检区域的淋巴结使用68Ga-Trivehexin PET/CT可能有助于准确分期。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A patient with left upper quadrant breast cancer who had 18 F-FDG PET/CT imaging underwent 68 Ga-Trivehexin PET/CT. 68 Ga-Trivehexin PET/CT showed higher radiotracer accumulation in the primary tumor, left internal mammary lymph nodes, and axillary lymph nodes compared with 18 F-FDG PET/CT. However, Trivehexin uptake was not observed in FDG-positive lymph nodes in the mediastinum and left hilar region. Benign cytological findings were noted in the biopsy of the subcarinal lymph node. This case demonstrates that the use of 68 Ga-Trivehexin PET/CT in suspicious lymph nodes in areas difficult to biopsy in breast cancer cases can contribute to accurate staging.
引用
- Kömek H, Güzel Y, Kaplan İ, et al. Superiority of 68 Ga-Trivehexin PET/CT Over 18 F-FDG PET/CT in the Evaluation of Lymph Nodes in Patients With Breast Cancer. Clin Nucl Med. 2024. PMID: 39601487. doi:10.1097/RLU.0000000000005585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。